Personalis: Leslie Grab, John Lyle
Personalis has appointed Leslie Grab as VP of intellectual property and John Lyle as VP of assay research and development.
Grab joins the firm from Verily Life Sciences where she was responsible for worldwide patent and trademark strategy and portfolio development across multiple product areas. Prior to that, she worked at the law firm of Kilpatrick Townsend & Stockton. Grab holds a PhD in biochemistry and molecular biology from Wake Forest University and a BA in chemistry from Catawba College, North Carolina. She earned her law degree from the University of North Carolina, Chapel Hill, where she also served as a post-doctoral associate researching the inter-relationship betwesen exosomes and ovarian cancer.
Lyle joins Personalis after 14 years at Pacific Biosciences where he most recently served as senior director of single-molecule sequencing, focusing on reagent, system, and application development of long-read, ultra-high accuracy sequencing. He received his PhD from Stanford University in microbiology and immunology and holds a BS from Bates College. Lyle also served as a post-doctoral fellow at the University of California, San Francisco, studying the structure and function of the centrosome.
Predictive Oncology: Nancy Chung-Welch, Charles Nuzum, Greg St. Clair
Predictive Oncology has appointed Nancy Chung-Welch, Charles Nuzum, and Greg St. Clair as independent directors. While Nuzum will serve on Predictive's audit committee, the firm noted that the other directors will join committees as soon as possible.
Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors. She previously served as director of business development at Cell Signaling Technology, as well as a director of business development at Thermo Fisher Scientific. She has also served as a technical marketing manager at Fisher Scientific.
Nuzum currently provides project-based financial consulting services to companies including McKesson, BioMarin, and AutoDesk. He serves on the board of directors of Dakshidin, NanoSynx, and Worldwide Structures. He previously cofounded and served as CFO of Tyburn Group. Prior to Tyburn, Nuzum served as controller of Merck KgaA pharmaceutical manufacturing subsidiary Dely. Before working at Dely, he served as cofounder, executive VP, and CFO of SCV Financial Services.
St. Clair is the founder and managing member of SunStone Consulting. Prior to SunStone, he served as national VP of CGI, ImrGlobal, and Orion Consulting. He also served as a national director for Coopers & Lybrand.
HalioDx: Stéphane Debono, Philippe Mourere
HalioDx has appointed Stéphane Debono as deputy CEO and Philippe Mourere as senior VP of commercial and business development. Debono is a cofounder of HalioDx. Mourere most recently served as senior VP of commercial operations at Ultivue, a developer of tissue biomarker assays for translational research.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.